证券日报网讯1月7日，爱尔眼科（300015）在互动平台回答投资者提问时表示，爱尔网络覆盖中国广大 城乡县域，截至2025年6月30日，公司境内医院355家，门诊部240家，详情请查阅爱尔眼科官网。 ...

格隆汇1月7日丨爱尔眼科(300015.SZ)在投资者互动平台表示，"小青葵"系列产品已实现量产。 ...

Core Viewpoint - The launch of the EVO ICL (V5) crystal implantation surgery in Gansu marks the introduction of a cutting-edge myopia correction technology, allowing local patients to access advanced treatment without traveling abroad [2][3]. Group 1: Technology and Innovation - The EVO ICL V5 crystal features a key advancement with an optical zone diameter increased from 5.8 mm to 6.1 mm, significantly enhancing night vision quality for patients, especially those with larger pupils, and reducing glare and halos [2]. - The V5 crystal improves the correction precision for moderate to low myopia to a range of 25 degrees, promoting personalized treatment options [2]. - The crystal has high biocompatibility and UV-blocking capabilities, having undergone over 30 years of clinical validation globally, making it a reliable surgical choice due to its non-cutting, safe, and reversible nature [2]. Group 2: Clinical Implementation and Recognition - The V5 technology's regular implementation in Lanzhou signifies its official approval by national authorities, allowing patients in Gansu and the northwest region to benefit from this advanced technology locally [3]. - A plaque ceremony was held to establish the "EVO ICL V5 Crystal Gansu Clinical Application Popularization Alliance," highlighting the collaboration between STAAR company and local hospitals, along with the certification of the first surgical expert in Gansu [3][5]. Group 3: Safety and Patient Experience - The V5 crystal maintains the safety foundation of its predecessor, with innovations primarily in optical design, supported by over 40 precise preoperative examinations to ensure safety and effectiveness [5]. - Different myopia correction techniques cater to various needs, with the EVO ICL (V5) particularly suited for patients with high myopia (over 600 degrees) and those requiring enhanced night vision, such as drivers [5]. - Patient testimonials shared during the event highlighted improvements in night vision and overall quality of life, resonating with the audience [5]. Group 4: Future Directions - The Lanzhou Eye Hospital plans to continue introducing global innovative technologies, ensuring a comprehensive range of surgical options and strict quality control to provide safer, more precise, and personalized visual quality enhancement solutions for patients in the northwest region [5].

证券日报网讯 1月6日，爱尔眼科在互动平台回答投资者提问时表示，公司专注眼科医疗，高度关注边 缘交叉学科的动态进展，在创新上鼓励"脑洞大开"，在工作中必须"脚踏实地"。 （文章来源：证券日报） ...

Group 1 - The company, Aier Eye Hospital (300015), focuses on its core business, providing multi-level ophthalmic diagnosis and treatment services for all age groups [1] - The company continuously monitors cutting-edge developments in marginal crossover fields [1]

（编辑 楚丽君） 证券日报网讯 1月6日，爱尔眼科在互动平台回答投资者提问时表示，"明眸远观福利"活动长期有效， 具体请参阅公司于2024年10月31日发布的《关于举办"上市十五年，回馈投资者"活动的公告》，可拨打 证券部电话0731-85136739，公司将协助联系落实。 ...

Group 1 - Multiple fund managers at Pengyang Fund have recently changed, including Li Qin, Wu Xiyan, Dai Jie, and Yang Aibin [2] - Li Qin has resigned from four funds, while Wu Xiyan has left three funds, and Dai Jie has stepped down from two funds [2] - Li Qin has been appointed as the fund manager for Pengyang Jingxin Mixed Fund and Pengyang Jingheng Six-Month Holding Mixed Fund [2] Group 2 - Wu Xiyan also resigned from the Pengyang Consumer Industry Mixed Initiation Fund in January 2025, which was terminated in August 2025, with a return of -6.68% for the A-class shares [3] - The Pengyang Growth Pioneer Mixed Fund, which Dai Jie left, was established in November 2021 and has seen a decline of 31.51% in net value since inception as of December 31, 2025 [3] - The fund's portfolio shows a 90.87% allocation to stocks and 5.5% to bonds, with major holdings including Tencent, Kweichow Moutai, and Meituan [3]

Core Viewpoint - The Medical Health Index (980016) closed at 6354.84 points, up 0.88%, with a trading volume of 29.705 billion yuan and a turnover rate of 1.0% on January 6 [1] Group 1: Index Performance - On the same day, 38 of the index's constituent stocks rose, with BGI Genomics leading with a 6.95% increase, while 11 stocks fell, with Zai Lab leading the decline at 3.72% [1] - The top ten constituent stocks of the Medical Health Index are detailed, with WuXi AppTec holding the highest weight at 10.23% and a latest price of 96.25 yuan, showing a 1.78% increase [1] Group 2: Market Capitalization - The total market capitalization of WuXi AppTec is approximately 287.187 billion yuan, while the highest market cap among the top ten is held by Hengrui Medicine at 418.542 billion yuan [1] - The market capitalization of the top ten stocks ranges from 489 million yuan for Kelun Pharmaceutical to 418.542 billion yuan for Hengrui Medicine [1] Group 3: Capital Flow - The net outflow of main funds from the constituent stocks totaled 471 million yuan, while retail investors saw a net inflow of 200 million yuan [1] - Detailed capital flow shows that WuXi AppTec had a net inflow of 180 million yuan from main funds, while Yeye Eye Care experienced a net outflow of 157 million yuan from retail investors [2]

证券代码：300015 股票简称：爱尔眼科 公告编号：2026-001 爱尔眼科医院集团股份有限公司 2025 年中期分红派息实施公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、爱尔眼科医院集团股份有限公司（以下简称"公司"）回购专用证券账户 中的股份 31,363,178 股不参与本次分红派息。本次分红派息将以公司最新总股本 9,325,396,670股扣除回购专户股份31,363,178股后的股本 9,294,033,492股为基 数，向全体股东每 10 股派 0.8 元人民币（含税），实际派发现金分红总额 =9,294,033,492 股×0.8 元/10 股=743,522,679.36 元（含税），不进行公积金转 增股本和送红股。 2、本次分红派息实施后计算除权除息价格时，按公司总股本（含回购股份） 折算每 10 股现金分红金额=现金分红总额÷公司总股本×10 股=743,522,679.36 元 /9,325,396,670 股×10 股=0.797309 元（保留六位小数，不四舍五入）。 3、公司本次分红派息实施后的除权除息参 ...

Core Viewpoint - Aier Eye Hospital announced a cash dividend plan for the first half of 2025, distributing 0.8 RMB per 10 shares to all shareholders, totaling 744 million RMB in cash dividends [1] Group 1: Dividend Details - The cash dividend distribution date is set for January 14, 2026, with the ex-dividend date on January 15, 2026 [1] - A total of 31.36 million shares held in the repurchase special securities account will not participate in this dividend distribution [1]